Claims
- 1. A composition of matter comprising a substantially pure compound denominated "Halistatin 3" and having the structural formula set forth below: ##STR3## wherein R.sub.1 =H; and R.sub.2 =CH.sub.2 CH.sub.2 CH(OH)CH.sub.2 OH.
- 2. The composition of matter according to claim 1 further comprising a pharmaceutically acceptable carrier.
- 3. A method of treating a host afflicted with a neoplastic disease selected from the group consisting of P388 leukemia, SF295 brain cancer, NCI 460 lung cancer, KM 2062 colon cancer, OVCAR-3 ovarian cancer, A 498 renal cancer, and SK-MEL 5 melanoma comprising administering to said host an amount of halistatin 3 sufficient to reduce the percent growth of said neoplastic disease to 50% and having the structural formula: ##STR4## wherein: R.sub.1 =H; and R.sub.2 =CH.sub.2 CH.sub.2 CH(OH)CH.sub.2 OH.
- 4. The method according to claim 3 wherein said halistatin 3 is administered in a pharmaceutically acceptable carrier.
Government Interests
This research was funded in part by Outstanding Investigator Grant CA 44344-01A1-06 awarded by the National Cancer Institute, DHHS. The United States government may have certain rights to this invention.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5328929 |
Pettit et al. |
Jul 1994 |
|
5352804 |
Pettit et al. |
Oct 1994 |
|